Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
17.03
+0.30 (1.79%)
Nov 20, 2024, 4:00 PM EST - Market closed
Pacira BioSciences Revenue
Pacira BioSciences had revenue of $168.57M in the quarter ending September 30, 2024, with 2.83% growth. This brings the company's revenue in the last twelve months to $694.96M, up 4.40% year-over-year. In the year 2023, Pacira BioSciences had annual revenue of $674.98M with 1.22% growth.
Revenue (ttm)
$694.96M
Revenue Growth
+4.40%
P/S Ratio
1.13
Revenue / Employee
$976,063
Employees
712
Market Cap
786.33M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 674.98M | 8.16M | 1.22% |
Dec 31, 2022 | 666.82M | 125.29M | 23.14% |
Dec 31, 2021 | 541.53M | 111.89M | 26.04% |
Dec 31, 2020 | 429.65M | 8.62M | 2.05% |
Dec 31, 2019 | 421.03M | 83.75M | 24.83% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Bioventus | 555.06M |
Evolus | 248.33M |
Cytek Biosciences | 201.21M |
Avid Bioservices | 142.36M |
Cronos Group | 111.23M |
PCRX News
- 6 days ago - Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee - GlobeNewsWire
- 14 days ago - Pacira Biosciences Inc. (PCRX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Pacira BioSciences Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 22 days ago - Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024 - GlobeNewsWire
- 4 weeks ago - Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer - GlobeNewsWire
- 7 weeks ago - Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025 - GlobeNewsWire
- 2 months ago - Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee - GlobeNewsWire
- 2 months ago - DOMA Perpetual Sends Letter to Board of Directors of Pacira Biosciences to Immediately Accelerate and Increase its Share Buyback Program to Enhance Return to Shareholders - PRNewsWire